Cell therapy products are unique — they require specialized facilities, expert personnel, and dedicated resources to efficiently support clients' development and manufacturing needs.
With more than 98,000 square feet of global development and manufacturing space, the PCT service platform offers globally harmonized GMP-compliant cell therapy manufacturing infrastructure. With facilities on both the east and west coasts of the United States, as well as a newly constructed facility in Yokohama, Japan (excepted to open in
Features of our controlled environment rooms (CERs or cleanrooms) include:
All of our GMP-compliant facilities offer cell and tissue cryogenic storage rooms with controlled access; live facility and equipment monitoring with automated alarm call-out; and UPS connection, ensuring the highest level of quality control and risk mitigation for product storage.
In addition to CERs and cryostorage rooms, our facilities house GMP-compliant material management facilities, QC and analytical laboratories, as well as product and process development laboratories.
Our U.S. facilities are FACT-accredited, hold all requisite licensures, are registered with the FDA as human cells, tissues, and cellular and tissue-based products (HCT/Ps) facilities, and maintain GMP-compliant quality systems. Our Yokohama facility is designed for compliance with Japan PMDA requirements.
The PCT Allendale facility in New Jersey is a 30,000-square-foot, GMP-compliant facility currently being expanded to house our growing operations, including expanding our capability to produce EU-compliant cell therapy products. With approximately 1,300 square feet of CERs to support PCT's existing and future clients, the Allendale facility offers capacity for projects in all stages of development ranging from process/product development to commercial cell therapy manufacturing, including large-scale fill/finish operations.
PCT Allendale is within close proximity to LaGuardia,
For more information on these capacity expansions, please read the press release.
The PCT Mountain View facility in California is a GMP-compliant, 25,000-square-foot cell therapy manufacturing facility with approximately 12,500 square feet of manufacturing operations space and 12,000 square feet of office space - ample capacity for projects in all stages of development ranging from process/product development to commercial cell therapy manufacturing, including fill/finish operations.
PCT maintains a California Drug Manufacturing License for the conduct of clinical trial manufacture and distribution of cell-based products. The facility also houses corporate offices for our California-based team.
PCT Mountain View is within close proximity to airports in San Francisco, Oakland and San Jose.
Hitachi Chemical’s Regenerative Medicine Business Sector has completed construction of PCT Yokohama, a GMP-compliant 47,000-square-foot cell therapy manufacturing facility with an initial three ISO 7 CERs with ISO 5 biological safety cabinets available (expandable up to 14 CERs total). The facility shares the same global PCT service platform, housing cryostorage, quality control laboratories, and manufacturing development capabilities. Validation of the facility to begin client manufacturing is expected to complete by April 2018.
PCT Yokohama is within close proximity to Yokohama, Haneda, and Narita airports.
For more information on PCT Yokohama, read the full press release: PCT Establishes Global Contract Development and Manufacturing Services Platform with Opening of Yokohama, Japan Facility.